Press coverage about Iovance Biotherapeutics (NASDAQ:IOVA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Iovance Biotherapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.4157776127558 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of research analysts recently commented on the company. BidaskClub upgraded Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 19th. B. Riley upped their price objective on Iovance Biotherapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, May 11th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Iovance Biotherapeutics in a research note on Friday, May 11th. ValuEngine upgraded Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research downgraded Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 18th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $22.69.

Shares of IOVA stock opened at $15.98 on Friday. Iovance Biotherapeutics has a 1 year low of $5.30 and a 1 year high of $19.90. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -11.33 and a beta of 2.72.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.02). sell-side analysts expect that Iovance Biotherapeutics will post -1.32 earnings per share for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Read More: Are analyst ratings accurate?

Insider Buying and Selling by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with's FREE daily email newsletter.